Vitrolife Group (VITR) Carnegie Healthcare Conference presentation summary

Market overview and opportunity

• Infertility affects 1 in 6 adults globally, representing a significant healthcare challenge and market opportunity.

• Less than 1% of the 134 million babies born annually are conceived via IVF, indicating substantial growth potential.

• Successful IVF treatment outcomes average around 33%, with access and affordability limiting broader adoption.

Strategic vision and growth targets

• Aims for annual organic revenue growth above 10% and an EBITDA margin over 33% within five years.

• Focuses on connecting products and services, expanding leadership, and accelerating growth in key markets.

• Prioritizes operational excellence, digitalization, and sustainability, including CO2 emissions reduction targets.

Innovation and product focus

• Advances penetration of Embryoscope and eWitness to improve IVF clinic workflow, automation, and traceability.

• Continues investment in R&D to bring new solutions to market faster.

• PGT-A genetic testing identifies chromosomally normal embryos, increasing pregnancy rates per transfer.